Drug-Coated Balloons for Infrainguinal Peripheral Artery Disease

Journal of Invasive Cardiology

Volumn 28, Issue 7, 2016, Pages 281-286

  Sethi, Sanjum S ^a   Lee, Michael S ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

femoropopliteal stenosis; paclitaxel coated balloon; restenosis

Indexed keywords

PACLITAXEL; ANTINEOPLASTIC AGENT; BIOCOMPATIBLE COATED MATERIAL;

ARTICLE; BALLOON; CLINICAL TRIAL (TOPIC); DRUG COATING; DRUG ELUTING STENT; FOLLOW UP; HUMAN; HYPERPLASIA; IN-STENT RESTENOSIS; MEDICAL TECHNOLOGY; META ANALYSIS (TOPIC); PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; REVASCULARIZATION; ADVERSE EFFECTS; ANGIOPLASTY; CONSTRICTION, PATHOLOGIC; DEVICES; DIAGNOSTIC IMAGING; FEMORAL ARTERY; LONG TERM ADVERSE EFFECTS; NEOINTIMA; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROCEDURES; VASCULAR PATENCY;

ANGIOPLASTY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG-ELUTING STENTS; FEMORAL ARTERY; HUMANS; HYPERPLASIA; LONG TERM ADVERSE EFFECTS; NEOINTIMA; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; VASCULAR PATENCY;

EID: 84976416299     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Dotter CT, Judkins MP. Transluminal treatment of arteriosclerotic obstruction. Description of a new technique and a preliminary report of its application. Circulation. 1964;30:654-670.
2. Schillinger M, Minar E. Percutaneous treatment of peripheral artery disease: novel techniques. Circulation. 2012;126:2433-2440.
3. Gray WA, Granada JF. Drug-coated balloons for the prevention of vascular restenosis. Circulation. 2010;121:2672-2680.
4. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, van de Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: A comparative randomized study. Cardiovasc Intervent Radiol. 1997;20:420-425.
5. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions? A randomized controlled study. Int Angiol. 1999;18:251-255.
6. Cejna M, Turnher S, Illiasch H, et al. PTA versus Palmaz stent in femoropopliteal artery obstructions: A multicenter prospective randomized study. J Vasc Interv Radiol. 2001;12:23-31.
7. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus Palmaz stent placement for femoropopliteal lesions. J Vasc Interv Radiol. 2001;12:935-942.
8. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879-1888.
9. Schillinger M, Sabeti S, Dick P, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation. 2007;115:2745-2749.
10. Drachman DE, Edelman ER, Seifert P, et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol. 2000;36:2325-2332.
11. Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: A meta-Analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582-589.
12. Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-645.
13. Lovich MA, Creel C, Hong K, Hwang CW, Edelman ER. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci. 2001;90:1324-1335.
14. Dake MD, Ansel GM, Jaff MR, et al; for the Zilver PTX Investigators. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-Arm clinical studies. J Am Coll Cardiol. 2013;61:2417-2427.
15. Fusaro M, Cassese S, Ndrepepa G, et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-Analysis of randomized trials. JACC Cardiovasc Interv. 2013;6:1284-1293.
16. Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6:274-281.
17. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004;110:810-814.
18. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: A potential drug delivery strategy following angioplasty. Am Heart J. 1991;122:1136-1140.
19. Rasheed Q, Cacchione JG, Berry J, et al. Local intramural drug delivery using an infusion balloon following angioplasty in normal and atherosclerotic vessels. Cathet Cardiovasc Diagn. 1994;33:240-245.
20. Creel CJ, Lovich MA, Edelman ER. Arterial paclitaxel distribution and deposition. Circ Res. 2000;86:879-884.
21. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol. 2000;35:1969-1976.
22. Scheller B, Speck U, Schmitt A, Bohm M, Nickenig G. Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. J Am Coll Cardiol. 2003;42:1415-1420.
23. Garcia L, Jaff MR, Metzger C, et al; the SUPERB Trial Investigators. Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: Twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8.
24. Laird JR, Katzen BT, Scheinert D, et al; RESILIENT Investigators. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: Twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3:267-276.
25. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689-699.
26. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102-108.
27. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358-1365.
28. Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: A meta-Analysis of randomized trials. Circ Cardiovasc Interv. 2012;5:582-589.
29. Tepe G, Laird J, Schneider P, et al; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502.
30. Rosenfield K, Jaff MR, White CJ, et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153.
31. FREERIDE Study: Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01960647. Accessed December 24, 2014.
32. Advance 18PTX Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery with a Paclitaxel-coated Balloon. Available at: http://clinicaltrials. gov/ct2/show/NCT00776906. Accessed December 24, 2014.
33. ILLUMENATE Pivotal, CVI Drug-Coated Balloon vs. Uncoated Balloon. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01858428. Accessed December 24, 2014.
34. Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: The DEBATE-SFA randomized trial (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery). JACC Cardiovasc Interv. 2013;6:1295-1302.
35. Fusaro M, Cassese S, Ndrepepa G, et al. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: A meta-Analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison. Int J Cardiol. 2013;168:4002-4009.
36. Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery. Available at: http://clinicaltrials.gov/ct2/show/NCT01728441.
37. Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency and clinical outcome after balloon-Angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv. 2010;76:1047-1054.
38. Scheinert D, Katsanos K, Zeller T, et al; ACHILLES Investigators. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290-2295.
39. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105-1109.
40. Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): A randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615-621.
41. Zeller T, Baumgartner I, Scheinert D, et al; IN.PACT DEEP Trial Investigators. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568-1576.
42. Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: The IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048-1056.
43. Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries. 2013. Available at: http://clinicaltrials. gov/ct2/show/NCT01870401. Accessed December 24, 2014
44. Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions (ADCAT). Available at: http://clinicaltrials.gov/ct2/show/NCT01763476. Accessed July 25, 2015
45. Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10-19.
46. Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831-840.
47. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13-23.